Oxbryta Litigation in 2026: Status, Settlements and Case Criteria for Plaintiff Firms

By Fadi Agour, J.D. · Updated November 10, 2026 · Facts last reviewed November 10, 2026

Key takeaways

• Oxbryta (voxelotor) was sold from November 2019 until its worldwide withdrawal in September 2024.
• There is no MDL. Federal cases are grouped before one judge in the Northern District of California.
• Confidential settlements in at least two cases were reported in May and June 2026. There is no global settlement.
• Pfizer contests the claims and has argued federal preemption.
• Strong files show a confirmed prescription, use in the sale window, a documented injury and the records behind it.

What Oxbryta was

Sickle cell disease is an inherited blood disorder in which red blood cells take on a rigid crescent shape. Those cells block blood flow and break down early, causing severe pain episodes known as vaso-occlusive crises, anemia and organ damage.

Oxbryta was designed to stop red cells from sickling by increasing hemoglobin's hold on oxygen. The FDA approved it in November 2019 for patients aged 12 and older and expanded it to younger children in 2021. It was developed by Global Blood Therapeutics, which Pfizer bought in October 2022 for $5.4 billion.

Why Pfizer withdrew it

On September 25, 2024, Pfizer withdrew Oxbryta worldwide after clinical data showed more pain crises and more deaths among patients taking it. A day later, European regulators recommended suspending its approval.

In one trial of children at high risk of stroke, 8 patients on Oxbryta died compared with 2 on placebo. In a second trial of patients with leg ulcers, 8 of 88 patients died. Most of those deaths were attributed to infections such as malaria or sepsis, and no study has shown the drug directly caused them.

The defense has evidence of its own. In August 2025, Pfizer said it had completed its data review and shared it with U.S. and European regulators. In April 2026, researchers published registry data in Blood Advances that reported no new safety signals.

Where the cases stand

The settlements were reported by a plaintiff firm tracking the dockets, not announced by Pfizer. Other cases are pending in California state court, including a wrongful death case in San Francisco.

The legal theories, and the defense

Most complaints are failure-to-warn claims. They allege Global Blood Therapeutics and Pfizer did not disclose emerging risks of pain crises, stroke and death quickly enough after the drug reached the market.

Pfizer's main defense so far is federal preemption: the argument that FDA rules prevented the companies from changing the label on their own, so state-law warning claims cannot proceed. The Supreme Court rejected that argument for brand-name drug labels in Wyeth v. Levine in 2009, but defendants still raise it case by case. How the Northern District of California rules will shape how much internal safety information comes out in discovery.

Injuries the lawsuits allege

These are allegations, not findings.

What this means for firms

• The universe is small. Oxbryta treated a rare disease and was on the market for under five years. Expect individual cases, not thousands.
• Screen hard. A strong file shows a confirmed prescription, use between November 2019 and September 2024, a documented injury or death during or after use, and the medical records behind it.
• Check the clock. Statutes of limitations vary by state and by the date of injury. Families with wrongful death claims face their own deadlines.
• Documentation decides value. In a settlement-driven phase, the cases with clean records move first.
• Expect a long tail. With trials set for 2027, cases filed now may resolve on the same track as the early ones.

Intake checklist for Oxbryta cases

1. Confirmed sickle cell diagnosis and Oxbryta prescription, with pharmacy records if possible.
2. Dates of first and last use.
3. The injury, its date and where it was treated.
4. Medical records that connect the timeline.
5. For a death: date of death, death certificate and the person who will represent the estate.
6. State of residence and treatment, to check the statute of limitations.

We screen mass tort claimants against the criteria each firm sets. See our lead standards, our 12-point checklist for vetting mass tort leads, current campaigns on our mass tort leads page, and how Oxbryta compares with larger dockets in the hottest mass torts of 2026.

FAQ

Is there an Oxbryta MDL?

No. As of November 2026, no MDL has been formed. Cases are filed individually, mostly in California state and federal courts.

Have any Oxbryta cases settled?

Confidential settlements in at least two individual cases were reported in May and June 2026. There is no global settlement.

When is the first Oxbryta trial?

A federal trial is set for September 13, 2027, in the Northern District of California.

What injuries do the lawsuits claim?

Vaso-occlusive crises, stroke, acute chest syndrome, organ failure and death.

Why was Oxbryta recalled?

Pfizer withdrew it worldwide in September 2024 after clinical data showed more pain crises and deaths among patients taking it.

Who made Oxbryta?

Global Blood Therapeutics developed it. Pfizer bought the company in October 2022.

About the author

Fadi Agour, J.D., is the founder and CEO of FadiLaw Marketing LLC, the Houston-based parent company of Best Case Leads, Real Performance Marketing, Masstortsco, and Redostar. His companies have made the Inc. 5000 list seven years in a row.

Sources

1. Drugwatch: Oxbryta lawsuit (updated June 3, 2026)
2. Robert King Law Firm: Oxbryta lawsuit 2026 updates (updated September 22, 2026)
3. Tavrn: Oxbryta withdrawal, the GBT acquisition and Pfizer's preemption defense
4. Saiontz & Kirk: Oxbryta recall and EMA suspension timeline
5. Shapiro Legal Group: Oxbryta litigation status 2026

This article is general information about pending litigation, not legal advice. Best Case Leads is not a law firm.

Exclusivity is limited by geography. Tell us your practice area and state, and we'll confirm what's open.